Nogest (Nomegestrol Acetate)

Nomegestrol acetate binds to progesterone receptors in the hypothalamic‑pituitary‑ovarian axis, suppressing the luteinizing hormone surge and thereby inhibiting ovulation. It also induces changes in the endometrium that make it unsuitable for implantation and, in menopausal regimens, balances estrogen effects.

The specific dose and regimen of Nogest are determined by the prescribing healthcare professional based on the individual’s medical history, indication, and local regulatory guidelines. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Nogest is contraindicated during known or suspected pregnancy because it is intended to prevent conception. Use while breastfeeding is generally discouraged unless the benefits to the mother clearly outweigh potential risks to the infant; a healthcare provider should evaluate each case.

To order Nogest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with many combined oral contraceptives that contain both estrogen and a progestin, Nogest provides a progestogen‑only option, which may be preferred for women who cannot tolerate estrogen. Its synthetic progestogen, nomegestrol acetate, offers strong receptor affinity and a favorable bleeding profile, though individual response varies.

Nogest tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat and direct sunlight to maintain potency throughout the shelf life.

Nogest is taken orally, usually once daily at the same time each day, as directed by the prescriber. For contraceptive use, a typical cycle consists of 21 days of active tablets followed by a hormone‑free interval, but the exact schedule should follow the healthcare professional’s guidance.

The most serious adverse events associated with Nogest include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), severe liver dysfunction, and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, jaundice, or signs of a severe allergic response.

Nogest should not be used by women who are pregnant, have a known hypersensitivity to nomegestrol acetate, have a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, or who are smokers over the age of 35. A thorough medical assessment by a qualified clinician is essential before initiation.